Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing long-term prophylactic Optivate treatment in severe haemophilia A
2012-004606-10Phase 4Completed
- Sponsor
- Bio Products Laboratory
- Start
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of factor viii + von Willebrand factor in hemophilia A, sponsored by Bio Products Laboratory. Primary endpoint: Immunogenicity of Optivate. Started Apr 2014; status: completed.
02
Drugs
factor viii + von Willebrand factor
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2012-004606-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004606-10.